CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$53.91 USD
+0.18 (0.34%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $53.50 -0.41 (-0.76%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRSP 53.91 +0.18(0.34%)
Will CRSP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Ascends But Remains Behind Market: Some Facts to Note
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
Other News for CRSP
CRSP June 7th Options Begin Trading
Buy Rating on Crispr Therapeutics AG Backed by Exa-cel’s Precision and Favorable Safety Profile
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies
Crispr Therapeutics: Now Is The Time To Buy
Crispr Therapeutics management to meet with Mizuho